Top Nano Cap Stock Movers: PATH, CERP, TELK, KIPS, DARA

Pompano Beach, FL -- (SBWIRE) -- 01/18/2013 -- Csrnewsdaily.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following Tuesday’s Top Gainers:-

NuPathe Inc (NASDAQ:PATH) added 7.24% and is trading at $3.55. NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Can PATH Continue To Move Higher? Find Out Here

Cereplast, Inc. (PINK:CERP) is higher 15.00% and is trading at $0.0115. Cereplast, Inc. (Cereplast) is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line), which replaces up to 90% of the petroleum-based content of traditional plastics with materials from renewable resources.

Can CERP Extend Rally? Find Out Here

Telik, Inc. (NASDAQ:TELK) fell 2.84% and is trading at $1.71. Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company’s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

How Should Investors Trade TELK Now? Find Out Here

Kips Bay Medical, Inc. (NASDAQ:KIPS) is higher 3.43% and is trading at $0.693. Kips Bay Medical, Inc. is a medical device company focused on developing, manufacturing and commercializing its external saphenous vein support technology (eSVS MESH) for use in coronary artery bypass grafting (CABG) surgery. The Company’s eSVS MESH is a nitinol mesh sleeve that, when placed over a saphenous vein graft during CABG surgery, is designed to improve the structural characteristics and performance of the vein graft.

How Should Investors React To KIPS Now? Find Out Here

DARA Biosciences Inc (NASDAQ:DARA) is lower 1.32% and is trading at $0.773. DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959.

Can DARA Extend Rally? Find Out Here

About Csrnewsdaily.com
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.

Disclaimer
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.

Contact:
Csrnewsdaily.com
info@csrnewsdaily.com